Abstract
Inflammation in the central nervous system (CNS) may occur as a result of trauma, infection or neurodegenerative stimuli and is characterized by activation of microglia, the resident immune cells of the CNS. Activated microglia proliferate rapidly, migrate to the site of injury or infection and elicit immune response by phagocytosis of cell debris, production of cytokines, chemokines and reactive oxygen species, and presentation of antigens to other immune cells. In addition, microglia participate in tissue repair by producing neurotrophic factors. However, when microglia are chronically activated, they become neurotoxic to the surrounding CNS parenchyma.
Chronic activation of microglia has been shown to augment neurodegeneration in Parkinson’s disease (PD), Alzheimer’s disease (AD), brain injury and number of other CNS pathologies. Identification of factors that control microglial activation, therefore, has become the major focus of recent research. A number of herbal and chemical compounds have been shown to attenuate microglial activation. However, these compounds exhibit non-specificity and produce unpleasant side-effects. Here, we provide a comprehensive review on some of the currently available drugs known to reduce microglial activation, their molecular targets and the subcellular signaling networks on which they act. We also review some of the newly emerging therapeutic avenues such as ‘epidrugs’ and finally emphasize on the importance of targeted drug delivery systems for alleviating microglia-mediated neurotoxicity.
Keywords: Microglia, inflammation, brain injury, neurodegeneration, retinoic acid, glucocorticoids, minocycline, miRNA, epigenetics.
CNS & Neurological Disorders - Drug Targets
Title:Potential Drugs Targeting Microglia: Current Knowledge and Future Prospects
Volume: 12 Issue: 6
Author(s): Parakalan Rangarajan, Ling Eng-Ang and S. Thameem Dheen
Affiliation:
Keywords: Microglia, inflammation, brain injury, neurodegeneration, retinoic acid, glucocorticoids, minocycline, miRNA, epigenetics.
Abstract: Inflammation in the central nervous system (CNS) may occur as a result of trauma, infection or neurodegenerative stimuli and is characterized by activation of microglia, the resident immune cells of the CNS. Activated microglia proliferate rapidly, migrate to the site of injury or infection and elicit immune response by phagocytosis of cell debris, production of cytokines, chemokines and reactive oxygen species, and presentation of antigens to other immune cells. In addition, microglia participate in tissue repair by producing neurotrophic factors. However, when microglia are chronically activated, they become neurotoxic to the surrounding CNS parenchyma.
Chronic activation of microglia has been shown to augment neurodegeneration in Parkinson’s disease (PD), Alzheimer’s disease (AD), brain injury and number of other CNS pathologies. Identification of factors that control microglial activation, therefore, has become the major focus of recent research. A number of herbal and chemical compounds have been shown to attenuate microglial activation. However, these compounds exhibit non-specificity and produce unpleasant side-effects. Here, we provide a comprehensive review on some of the currently available drugs known to reduce microglial activation, their molecular targets and the subcellular signaling networks on which they act. We also review some of the newly emerging therapeutic avenues such as ‘epidrugs’ and finally emphasize on the importance of targeted drug delivery systems for alleviating microglia-mediated neurotoxicity.
Export Options
About this article
Cite this article as:
Rangarajan Parakalan, Eng-Ang Ling and Thameem Dheen S., Potential Drugs Targeting Microglia: Current Knowledge and Future Prospects, CNS & Neurological Disorders - Drug Targets 2013; 12 (6) . https://dx.doi.org/10.2174/18715273113126660175
DOI https://dx.doi.org/10.2174/18715273113126660175 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Treatment of Fabry Disease: Current and Emerging Strategies
Current Pharmaceutical Biotechnology Lipid-Based Nanocarriers for CNS-Targeted Drug Delivery
Recent Patents on CNS Drug Discovery (Discontinued) Which Drugs for the Control of Fever in Critical Patients
Current Drug Targets Targeting JAK3 Tyrosine Kinase-Linked Signal Transduction Pathways with Rationally-Designed Inhibitors
Anti-Cancer Agents in Medicinal Chemistry β-Sheet Breakers for Alzheimers Disease Therapy
Current Drug Targets Arterial Spin Labeling Perfusion MRI in Alzheimers Disease
Current Medical Imaging Potential Role of Polyphenols in the Prevention of Cardiovascular Diseases: Molecular Bases
Current Medicinal Chemistry Can FreeSurfer Compete with Manual Volumetric Measurements in Alzheimer’s Disease?
Current Alzheimer Research Interactions of VDAC with Proteins Involved in Neurodegenerative Aggregation: An Opportunity for Advancement on Therapeutic Molecules
Current Medicinal Chemistry An Association of Virus Infection with Type 2 Diabetes and Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Endothelial Function Assessment in Complicated Hypertension
Current Pharmaceutical Design Patent Annotations
Recent Patents on Anti-Cancer Drug Discovery Left Anterior Temporal Lobe Sustains Naming in Alzheimers Dementia and Mild Cognitive Impairment
Current Alzheimer Research Transgenic Overproduction of Omega-3 Polyunsaturated Fatty Acids Provides Neuroprotection and Enhances Endogenous Neurogenesis After Stroke
Current Molecular Medicine Recently Patented Applications of Homologous Cellular and Extracellular Agents as Therapeutics or Targets for the Prevention of Restenosis Post- Angioplasty
Recent Patents on Cardiovascular Drug Discovery Mechanisms of Inflammatory Atherosclerosis in Rheumatoid Arthritis
Current Immunology Reviews (Discontinued) Stress, Depression, Resilience and Ageing: A Role for the LPA-LPA1 Pathway
Current Neuropharmacology The Therapeutic Potential of Neuro-EPO Administered Nasally on Acute Cerebrovascular Disease
Current Psychopharmacology Synthesis, Antioxidant and Anti-inflammatoy Effects of Antioxidant Acid Amides with GABA and N-Acyl-pyrrolidin-2-ones
Current Chemical Biology Dry Age-Related Macular Degeneration: Recent Progress of Therapeutic approaches
Current Molecular Pharmacology